Loading...
•
Jun 30, 2024
Korro Bio Q2 2024 Earnings Report
Korro Bio reported financial results for the second quarter of 2024 and provided an update on its recent progress and anticipated milestones.
Key Takeaways
Korro Bio reported a net loss of $21.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $187.8 million as of June 30, 2024, providing a cash runway into the second half of 2026.
First-in-human trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024.
Preclinical data presented at ATS demonstrated KRRO-110's ability to correct alpha-1 antitrypsin (AAT) protein resulting in >70% of circulating protein to be M-AAT and concomitantly reducing the Z-AAT protein.
Korro Bio ended the second quarter of 2024 with $187.8 million in cash, cash equivalents and marketable securities.
Cash runway into second half of 2026 to fund anticipated completion of KRRO-110 FIH trial and progress additional pipeline candidates.
Forward Guidance
Korro Bio anticipates regulatory filing of KRRO-110 in AATD on track for the second half of 2024, interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients anticipated in the second half of 2025 and completion of the Phase 1/2 clinical trial for KRRO-110 expected in 2026.
Positive Outlook
- Regulatory filing of KRRO-110 in AATD on track for the second half of 2024.
- Interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients anticipated in the second half of 2025.
- Completion of the Phase 1/2 clinical trial for KRRO-110 expected in 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...